Bide Pharmatech (SH:688073) Xin Lang Cai Jing·2025-10-13 01:38Core Viewpoint - On October 10, Bid Pharma experienced a decline of 6.71% in stock price, with a trading volume of 64.09 million yuan, indicating market volatility and investor sentiment towards the company [1]. Financing Summary - On the same day, Bid Pharma had a financing purchase amount of 7.73 million yuan, with a net financing purchase of 4.02 million yuan after accounting for repayments [1]. - The total financing and securities balance for Bid Pharma reached 39.98 million yuan, which constitutes 1.28% of its market capitalization, indicating a low financing balance compared to the past year [1]. - In terms of securities lending, there were no shares sold or repaid on October 10, with the securities lending balance also at zero, suggesting a high level of investor confidence or lack of short-selling activity [1]. Company Profile - Shanghai Bid Pharma Technology Co., Ltd. was established on April 27, 2007, and went public on October 11, 2022. The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [2]. - The main revenue components include: 43.26% from molecular building block heterocyclic compounds, 23.32% from aromatic compounds, 16.36% from aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [2]. - As of June 30, 2025, Bid Pharma reported a revenue of 628 million yuan, representing a year-on-year growth of 17.91%, and a net profit attributable to shareholders of 73.41 million yuan, reflecting a 41.60% increase year-on-year [2]. Shareholder Information - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. - As of June 30, 2025, the company had 3,782 shareholders, an increase of 4.76% from the previous period, with an average of 11,431 circulating shares per shareholder, a decrease of 4.55% [2][3]. - Notable institutional shareholders include China Europe Medical Health Mixed A, which holds 4.25 million shares, and Agricultural Bank of China Medical Health Stock, which increased its holdings by 177,500 shares [3].